Short answer
Emergent BioSolutions Inc. (EBS) filed an 8-K current report with the SEC on June 29, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 7.01 (Regulation FD Disclosure). $52.7 million ASPR modification for ACAM2000 smallpox vaccine supply.
Emergent BioSolutions Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- $52.7 million ASPR modification for ACAM2000 smallpox vaccine supply
- Option Year 7 exercised under Emergent’s existing 10-year U.S. government contract
- June 2026 deliveries include vaccine doses, ancillaries, and diluent replacement lots
- Remaining diluent balance due by December 2026
- Government demand supports near-term ACAM2000 revenue visibility and production utilization
Item 7.01 · Regulation FD Disclosure
- Emergent BioSolutions issued a June 29, 2026 press release announcing Modification No. 15
- Modification No. 15’s terms and financial impact require review of Exhibit 99.1
- Reg FD disclosure makes the announcement publicly available to all investors simultaneously
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Emergent BioSolutions Inc. 8-K filings
Get the next EBS 8-K as it lands
Follow EBS for push alerts, or ask the research agent what this filing means.